Candida auris is a highly drug-resistant, hospital-acquired fungal pathogen. With limited treatment options, here is an overview of some of the next-generation antifungals as well as combination therapeutics.
Dallas J. Smith, PharmD
Advertisement
Smith, PharmD, is an epidemiologist, Mycotic Diseases Branch, CDC.(https://orcid.org/0000-0001-5707-528X)
Articles by Dallas J. Smith, PharmD
Advertisement
Latest Updated Articles
Advertisement
Advertisement
Trending on Contagion Live
1
US Completely Revamps Childhood Vaccine Schedule to Resemble Small European Country
2
Unlocking New Defenses: The Changing Landscape of Candida auris Management
3
What's New in 2025: From the CLSI Subcommittee on Antimicrobial Susceptibility Testing
4
Training Healthcare Professionals to Treat High-Consequence Infectious Disease
5